Newly discovered molecule may explain reduced muscle mass in type 2 diabetes
en-GBde-DEes-ESfr-FR

Newly discovered molecule may explain reduced muscle mass in type 2 diabetes


Researchers at Karolinska Institutet have discovered a previously unknown molecule that may explain why people with type 2 diabetes often suffer from muscle weakness and muscle loss – a condition that has a major impact on quality of life and overall health.
In the new study, published in Sciences Advances, researchers have identified a previously unknown molecule, TMEM9B-AS1, which may explain why people with type 2 diabetes often suffer from muscle weakness and loss of muscle mass. The molecule is a long non-coding RNA that plays an important role in regulating cellular functions.
The researchers discovered that TMEM9B-AS1 is significantly reduced in skeletal muscles in individuals with type 2 diabetes, and its absence disrupts the machinery needed to build new muscle proteins.
"Our study shows that TMEM9B-AS1 supports the stability of MYC, a key gene that drives the production of ribosomes – the factories that manufacture proteins. Without this RNA molecule, MYC becomes unstable, and muscle cells lose their ability to maintain normal protein production. This may help explain the muscle deterioration we often see in people with metabolic diseases," says first author Ilke Sen, affiliated researcher at the Department of physiology and parmacologypharmacology, Karolinska Institutet.
The study was conducted in collaboration with researchers from the Mondor Institute for Biomedical Research in Paris, France, and the University of Innlandet, Lillehammer, Norway. See the study for funders and any conflicts of interest.
Publication: ‘Down-regulation of human-specific lncRNA TMEM9B-AS1 in skeletal muscle of people with type 2 diabetes affects ribosomal biogenesis’, Ilke Sen, Jonathon A. B. Smith, Elena Caria, Iurii Orlov, Mladen Savikj, Aidan J. Brady, Kristian Lian, Stian Ellefsen, Juleen R. Zierath, Anna Krook, Sciences Advances, online 9 July 2025, doi: 10.1126/sciadv.ads4371
Angehängte Dokumente
  • Ilke Sen.Photo: Johannes Frandsén
Regions: Europe, Sweden, France, Norway
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Referenzen

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Wir arbeiten eng zusammen mit...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement